Andrea S. Blevins Primeau, PhD, MBA

Adding vistusertib to treatment with paclitaxel does not improve outcomes in patients with platinum-resistant or -refractory ovarian cancer, a phase 2 trial suggests.

Among older patients with diabetes, metformin was associated with a reduced risk of cancer, but the combination of aspirin and metformin was associated with an increased risk of cancer death.

Alisertib monotherapy has shown activity in postmenopausal patients with endocrine-resistant, HER2-negative, metastatic breast cancer, but it was not able to restore sensitivity to fulvestrant in this patient population.

The Breast Cancer Index can predict benefit from ovarian function suppression in premenopausal patients with HR+, early-stage breast cancer.

Patients with HR+/HER2-, intermediate-risk, early breast cancer can forgo chemotherapy without increasing their risk of late recurrence, updated data suggest.

Adding chemotherapy to endocrine therapy leads to greater cognitive impairment in postmenopausal patients with breast cancer, a study suggests.

Racial disparities in outcomes of HR+, HER2- breast cancer may not be explained by differences in treatment, an analysis suggests.